
What We’re Reading: Eli Lilly to Buy Prevail Therapeutics; Extra Doses of Pfizer Vaccine; Breast Cancer Drug Approved
Eli Lilly & Co is set to acquire Prevail Therapeutics Inc for almost $1 billion; Pfizer’s coronavirus disease 2019 vaccine vials found to contain extra doses; a new treatment has been approved for patients with advanced breast cancer.
Eli Lilly Set to Acquire Prevail Therapeutics
With a goal of adding gene therapies to its portfolio, pharma giant Eli Lilly will purchase Prevail Therapeutics, a biotech firm specializing in gene therapies meant to slow or stop underlying disease processes in neurodegenerative diseases (eg,
FDA to Allow Pharmacists to Administer Additional COVID-19 Vaccine Doses
Originally thought to only hold 5 doses, Pfizer’s vials containing its coronavirus disease 2019 (
MacroGenics Reportedly Receives FDA Approval for Breast Cancer Drug
MacroGenics, a biopharmaceutical company focused on developing monoclonal antibodies against cancer, has received FDA approval for its drug margetuximab-cmkb (Margenza) plus chemotherapy to treat patients with advanced breast cancer,
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.